Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT06445907
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06444880
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
Phase 2
Suspended
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT06439485
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 600
- Registration Number
- NCT06434337
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT06434363
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
Phase 1
Suspended
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT06434350
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Virtual, Group-Based, Expressive Writing Intervention for Survivors of Adolescent and Young Adult Cancer
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06434402
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determinants of Health
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2000
- Registration Number
- NCT06431347
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Goals of Care Discussion for Patients with Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT06420206
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
Early Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06414902
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath